SCHEMBL7069967

SCHEMBL7069967

O=C(c1ccccc1)c1ccc(Oc2ccccc2CC2CCNCC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 8/20 0.45
SLC6A4 P31645 8/20 0.45
SLC6A3 Q01959 7/20 0.45
CYP2D6 P10635 2/20 0.44
ELANE P08246 3/20 0.43
HTR1A P08908 2/20 0.43
KCNH2 Q12809 1/20 0.43
GBA1 P04062 1/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SRD5A2 P31213 2/20 0.41
POLB P06746 1/20 0.40
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7526768 0.86 SLC6A4 (0.56) SLC6A2SLC6A4SLC6A3CYP2D6HTR1A
SCHEMBL7069973 0.84 GBA1 (0.56) ELANEGBA1ALDH1A1SMN1; SMN2SRD5A2
SCHEMBL6925382 0.83 SLC6A4 (0.48) SLC6A2SLC6A4SLC6A3CYP2D6HTR1A
SCHEMBL6922676 0.82 SLC6A4 (0.59) SLC6A2SLC6A4SLC6A3HTR1AGBA1
SCHEMBL6923739 0.81 SLC6A4 (0.50) SLC6A2SLC6A4SLC6A3HTR1AKCNH2
SCHEMBL6926571 0.81 SLC6A4 (0.47) SLC6A2SLC6A4SLC6A3CYP2D6HTR1A
SCHEMBL6926391 0.79 SLC6A4 (0.54) SLC6A2SLC6A4SLC6A3HTR1AKCNH2
SCHEMBL6923820 0.78 SLC6A4 (0.43) SLC6A2SLC6A4SLC6A3HTR1AGBA1
SCHEMBL1155985 0.78 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3CYP2D6HTR1A
SCHEMBL6929844 0.78 SLC6A4 (0.53) SLC6A2SLC6A4SLC6A3CYP2D6HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6518284-B2 For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) 2003-02-11 US claimed
US-20020038031-A1 New 4 - substituted piperidines ORJALES VENERO AURELIO (ES) 2002-03-28 US claimed
EP-1002794-A1 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) 2000-05-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038031-A1 New 4 - substituted piperidines ADRA2C, ADRB2, ADRB1 SLC6A2 12/4885SLC6A4 11/4885SLC6A3 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.